Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the pharmacokinetics (PK) and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with moderate hepatic impairment and in matched healthy participants.
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort 1: Moderate Hepatic Impairment | Experimental | Participants with moderate hepatic impairment will receive single dose of VX-121/TEZ/D-IVA . |
|
| Cohort 2: Matched Healthy Participants | Experimental | Healthy participants will receive single dose of VX-121/TEZ/D-IVA. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| VX-121/TEZ/D-IVA | Drug | Fixed-dose combination tablets for oral administration. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of VX-121, TEZ, D-IVA, and Relevant Metabolites | Cohort 1: Pre-dose up to Day 23; Cohort 2: Pre-dose up to Day 13 | |
| Area Under the Concentration Versus Time Curve (AUC) of VX-121,TEZ, D-IVA, and Relevant Metabolites | Cohort 1: Pre-dose up to Day 23; Cohort 2: Pre-Dose up to Day 13 | |
| Fraction Unbound (fu) for VX-121 and D-IVA in Plasma | Cohorts 1 and 2: Pre-dose up to Day 2 | |
| Unbound Maximum Observed Concentration (Cmax ub) for VX-121 and D-IVA | Cohorts 1 and 2: Pre-dose up to Day 2 | |
| Unbound Area Under the Concentration Versus Time Curve (AUC ub) of VX-121 and D-IVA | Cohorts 1 and 2: Pre-dose up to Day 2 |
| Measure | Description | Time Frame |
|---|---|---|
| Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Cohort 1: Day 1 up to Day 32; Cohort 2: Day 1 up to Day 17 |
Not provided
Key Inclusion Criteria:
Cohort 1: Participants with Moderate Hepatic Impairment
Cohort 2: Matched Healthy Participants
Key Exclusion Criteria:
Cohort 1: Participants with Moderate Hepatic Impairment
Cohort 2: Matched Healthy Participants
Other protocol defined Inclusion/Exclusion criteria may apply.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinical Pharmacology of Miami, LLC | Miami | Florida | 33014-3616 | United States | ||
| GCP Research |
Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003550 | Cystic Fibrosis |
| ID | Term |
|---|---|
| D010182 | Pancreatic Diseases |
| D004066 | Digestive System Diseases |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| St. Petersburg |
| Florida |
| 33705 |
| United States |
| D030342 |
| Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D007232 | Infant, Newborn, Diseases |